Westlake Village BioPartners is a people-first life science venture capital firm that incubates and builds biotech companies by pairing world-class entrepreneurs with hands-on support and capital from ideation through commercial impact.
Their most common stage is series-b (42% of deals). Average disclosed round size is $136.4M (across 22 rounds with reported amounts).
Portfolio
19
Fund Size
$450M
Top Stage
Series B
Last 12 Mo
0
Team
Beth Seidenberg, MD
Founding Managing Director
David Allison, PhD
Managing Director
Mira Chaurushiya, PhD
Managing Director
Desmond Padhi, PharmD
Operating Partner
Kelli McKeirnan
Director of Administration
Brogan Perrelli, CPA
VP of Finance and Operations
Lauren Popov, PhD
Associate
Armando Alvarez, CPA
Finance Manager
Jennifer Kercher, JD
General Counsel
Beth Seidenberg
Founding Managing Director
Sean Harper
Co-founding Managing Director
Mira Chaurushiya
Managing Director
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Latigo Biotherapeutics | Series B | $150M | Mar 2025 |
 ArsenalBio | Unknown | $325M | Sep 2024 |
| AArsenal Biosciences | Series C | $325M | Jan 2024 |
| KKyverna Therapeutics | Series B | $60M | Aug 2023 |
 Kate | Series A | $51M | Jun 2023 |
| KKate Therapeutics | Series A | $51M | Jun 2023 |
| DDantari | Series A | $47M | Dec 2022 |
| AAcelyrin, Inc | Series C | $300M | Sep 2022 |
| AAcelyrin | Series C | $300M | Sep 2022 |
| EElectra Therapeutics | Series B | $84M | Feb 2022 |
 Kyverna | Series B | $85M | Jan 2022 |
| AArsenal Bio | Series B | $220M | Jan 2022 |
 Capsida | Series A | $50M | Apr 2021 |
 Neuron23 | Series B | $113.5M | Dec 2020 |
| AAcelyrin | Series A | — | Jan 2020 |
| TTmunity | Series B | $75M | Oct 2019 |
 Tmunity Therapeutics | Series B | $75M | Oct 2019 |
| ArsenalBio | Series A | $85M | Oct 2019 |
| EExpansion Therapeutics | Series A | $80M | Jan 2018 |
| CCapsida Biotherapeutics | Series A | $140M | — |
| NNeuron23 Inc | Series C | $100M | — |
| NNeuron23 Inc | Series A | $33.5M | — |
| AAcelyrin, Inc | Series B | — | — |
| AAcelyrin | Series B | $250M | — |
Top Co-Investors
Last updated: 8 September 2026